CryoPort (NASDAQ:CYRX) Stock Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

CryoPort, Inc. (NASDAQ:CYRX)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $9.27 and traded as high as $9.33. CryoPort shares last traded at $9.22, with a volume of 600,372 shares trading hands.

Analysts Set New Price Targets

Several brokerages have weighed in on CYRX. Wall Street Zen lowered CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Craig Hallum began coverage on CryoPort in a research report on Monday, March 30th. They issued a “buy” rating and a $15.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research report on Friday, March 27th. Finally, Needham & Company LLC upped their target price on CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.94.

CryoPort Trading Up 0.2%

The firm has a 50-day simple moving average of $8.48 and a two-hundred day simple moving average of $9.26. The company has a market capitalization of $460.21 million, a price-to-earnings ratio of 6.99 and a beta of 1.68.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $45.45 million during the quarter, compared to analyst estimates of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. On average, sell-side analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Insider Activity

In other news, insider Mark W. Sawicki sold 3,235 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $25,880.00. Following the transaction, the insider owned 103,697 shares of the company’s stock, valued at approximately $829,576. This represents a 3.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jerrell Shelton sold 7,918 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the transaction, the chief executive officer directly owned 1,054,501 shares in the company, valued at approximately $8,436,008. This represents a 0.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 59,939 shares of company stock valued at $471,183. Insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CYRX. AQR Capital Management LLC increased its holdings in shares of CryoPort by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock valued at $1,597,000 after acquiring an additional 194,482 shares during the last quarter. Creative Planning acquired a new position in shares of CryoPort during the 2nd quarter valued at about $96,000. Rhumbline Advisers increased its holdings in shares of CryoPort by 17.6% during the 2nd quarter. Rhumbline Advisers now owns 92,098 shares of the company’s stock valued at $687,000 after acquiring an additional 13,778 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of CryoPort by 24.4% during the 2nd quarter. American Century Companies Inc. now owns 88,876 shares of the company’s stock valued at $663,000 after acquiring an additional 17,459 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of CryoPort during the 2nd quarter valued at about $254,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.